PharmaJet to Showcase Advancements in Intradermal Needle-Free Delivery at ASTMH Annual Meeting
PharmaJet®, a leading company focused on transforming injectable delivery through needle-free technology, announced that it will present new results and strategic insights from its intradermal (ID) programs at the upcoming American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, scheduled for November 9–13 at the Metro Toronto Convention Centre in Toronto, Ontario, Canada.
The ASTMH Annual Meeting is recognized as one of the most influential global scientific gatherings devoted to combating tropical infectious diseases and improving public health outcomes, particularly in underserved regions around the world. Each year, the event brings together clinicians, researchers, healthcare policymakers, product developers, and nonprofit organizations who share a common mission: reducing the global burden of diseases that disproportionately affect low- and middle-income countries. Within this context, PharmaJet’s participation highlights the growing importance of intradermal needle-free delivery platforms in accelerating vaccine accessibility, enhancing immunization performance, and supporting development of next-generation biologics.
Focus on Intradermal Delivery to Improve Global Health
PharmaJet continues to drive innovation in vaccination and therapeutics by offering a needle-free system that replaces traditional hypodermic needles. The company’s flagship Tropis® intradermal delivery system has increasingly gained interest from drug developers who aim to improve vaccine performance, reduce vaccine hesitancy, and streamline administration across diverse healthcare environments—including resource-constrained settings.
A key theme in PharmaJet’s presence at ASTMH is the growing acknowledgment that intradermal delivery represents an important evolution in the injectable landscape. As global vaccination programs aim to increase coverage while optimizing dose efficiency, the ability to deliver precise intradermal doses without a needle offers significant public health value.
Intradermal administration enables targeted delivery of antigens to skin layers rich in immune-presenting cells. This can result in strong immune responses at lower vaccine doses, allowing public health programs to extend vaccine supplies and reduce cost per dose—an important consideration when responding to disease outbreaks or routine immunization needs in low-resource regions.
Presentations Led by Paul LaBarre
During the ASTMH meeting, Paul LaBarre, Senior Vice President of Global Business Development at PharmaJet, will deliver several presentations that provide new data and insights about intradermal vaccine delivery, implementation learnings from real-world immunization campaigns, and future opportunities for expanding patient access. Each session reflects PharmaJet’s commitment to collaborating with global partners to strengthen vaccine delivery systems and accelerate development of preventative therapeutics targeting a range of tropical diseases.
LaBarre’s scheduled presentations include:
- “Novel technologies for intradermal delivery of fractional-dose inactivated poliomyelitis vaccine: Review of implementation research and implications for equitable neglected tropical disease vaccine access”
Date: Monday, November 10
Time: 12:30 p.m. – 2:15 p.m. (Eastern Time) This session will examine emerging strategies supporting intradermal fractional dosing of inactivated poliovirus vaccine (IPV). The presentation will highlight how new ID technologies can improve dose allocation, simplify operations, and expand equitable access to critical vaccines used in neglected tropical disease prevention. The talk will draw on findings from implementation programs, offering practical perspectives about how global health organizations can adopt fractional-dose ID delivery methods. - “Evaluating the Impact of Needle-free Intradermal Delivery of Inactivated Polio Vaccine in Nigeria’s Routine Immunization Program”
Date: Tuesday, November 11
Time: 12:00 p.m. – 1:45 p.m. This presentation will share results from the use of needle-free intradermal IPV during routine childhood immunization in Nigeria—an area where polio eradication remains a priority. Despite major progress, periodic IPV stock challenges and gaps in immunization coverage have posed ongoing barriers. Data from this study evaluate how Tropis needle-free delivery may support improved coverage, streamlined workflow, and stronger community acceptance. - “Novel non-invasive vaccine delivery practices may increase access and acceptability of latent tuberculosis infection screening”
Date: Wednesday, November 12
Time: 11:00 a.m. – 12:45 p.m. This presentation will explore emerging opportunities to deploy non-invasive delivery technologies to improve tuberculosis screening. Tuberculosis remains one of the world’s deadliest infectious diseases, particularly in low-resource countries. Innovative simplified vaccine and screening delivery techniques could help increase patient engagement, enhance healthcare worker capacity, and reduce hesitancy—all contributing to early detection and preventive treatment.
These sessions together illustrate how intradermal needle-free technology can serve as a versatile platform across diverse infectious disease targets, including polio and tuberculosis, where new solutions are urgently needed.
Validated Needle-Free Technology Supporting Global Partnerships
PharmaJet’s needle-free systems have been validated in more than 12 million injections worldwide, demonstrating consistent performance across real-world use cases. The technology has shown advantages in patient comfort, operational efficiency, and dose accuracy.
Traditional needles have long been associated with pain, accidental sticks, possible cross-contamination, and reluctance among both patients and clinicians. Needle fear and pain remain widely documented contributors to vaccine hesitancy. By eliminating the needle, Tropis supports higher acceptability and simplifies disposal—offering important benefits for immunization programs facing infrastructure constraints.
“Needles have been associated with pain, adverse events, and hesitation. Our needle-free systems have been validated with over 12 million injections, and our partners are finding new ways to leverage the precision, acceptability, and other unique benefits of needle-free to make their candidate products even better,” said Paul LaBarre, Senior Vice President of Global Business Development at PharmaJet.
LaBarre emphasized that the strongest momentum behind needle-free ID adoption comes from pharmaceutical partners who are discovering that intradermal delivery offers more than convenience. Beyond its practical advantages, emerging data suggest that intradermal administration may enhance immunological performance, enabling developers to optimize their antigen programs and increase the probability of achieving targeted immune responses.
“While our patented needle-free technology has been shown to improve immunization coverage with high acceptability and cost-effectiveness, it is our pharmaceutical partner data that really excite us—when they discover the immunological benefits of intradermal delivery and develop new strategies to optimize their candidate products using Tropis,” LaBarre continued.
Growing Adoption Among Drug Developers
As more pipeline vaccines and biologic candidates target indications where dermal immune activation plays an important role, intradermal delivery solutions are attracting increased interest. Particularly in the areas of neglected tropical diseases—such as dengue, chikungunya, yellow fever, tuberculosis, and polio—dose sparing approaches have the potential to extend global supplies, especially in surge scenarios.
PharmaJet’s Tropis system provides a standardized, reliable method to administer precise intradermal doses without the technique-sensitivity required for traditional intradermal needle injections. This makes training easier and helps ensure reproducibility across varied care settings.
The company is actively engaged in partnerships with global health organizations, research institutes, vaccine developers, and immunization programs to integrate Tropis into both ongoing clinical development and real-world implementation efforts. Early-stage clinical results and post-market analyses suggest that combining ID administration with needle-free technology offers meaningful improvements in patient experience while maintaining or enhancing immunological outcomes.
Advancing Toward Equitable Access
A core component of PharmaJet’s mission is to support equitable access to vaccines, especially in low-resource regions where disease burden is highest. By simplifying vaccine administration, reducing reliance on a cold chain in some cases, and improving healthcare worker efficiency, Tropis needle-free intradermal delivery may enable broader distribution of critical vaccines.
Accordingly, the company’s participation in ASTMH aligns with the broader goals of strengthening global disease response, improving routine immunization, and delivering innovative delivery tools that complement emerging vaccine platforms.
PharmaJet’s continued collaboration with innovators in global health reflects the company’s belief that delivery matters as much as the product itself. As biologics and vaccines become more sophisticated, companies must consider how to deliver these products effectively, safely, and acceptably—especially in remote or underserved geographies.
Through accumulated real-world experience, strong partner engagement, and the growing evidence base supporting intradermal needle-free immunization, PharmaJet is positioned to play an increasing role in global health initiatives seeking to expand equitable access to lifesaving interventions.
As the ASTMH Annual Meeting approaches, PharmaJet will showcase how intradermal delivery and needle-free systems can strengthen immunization strategy, enhance product development, and generate new opportunities to overcome barriers in tropical disease prevention and management.
Source Link: https://www.businesswire.com/
